The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of Kohne's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901.
Ayako Doi
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Yasushi Tsuji
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Hiraku Fukushima
No relevant relationships to disclose
Kazuteru Hatanaka
No relevant relationships to disclose
Hirohito Naruse
No relevant relationships to disclose
Hiroyuki Okuda
No relevant relationships to disclose
Takaya Kusumi
No relevant relationships to disclose
Koshi Fujikawa
No relevant relationships to disclose
Yasuo Takahashi
No relevant relationships to disclose
Soh Saitoh
No relevant relationships to disclose
Shinya Kajiura
No relevant relationships to disclose
Ayumu Hosokawa
No relevant relationships to disclose
Yutaka Watanabe
No relevant relationships to disclose
Fumiyasu Yamamoto
No relevant relationships to disclose
Mineo Kudo
No relevant relationships to disclose
Nobuaki Akakura
No relevant relationships to disclose
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck; Otsuka; Synergy International; Taiho Pharmaceutical; Yakult
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult